| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 999.58M | 1.01B | 914.36M | 1.03B | 823.26M | 696.57M |
| Gross Profit | 251.81M | 789.90M | 170.09M | 185.41M | 137.56M | 112.46M |
| EBITDA | 91.21M | 92.49M | 49.06M | 128.29M | 86.31M | 34.48M |
| Net Income | 2.09M | -2.87M | -39.30M | 58.81M | -4.26M | -31.80M |
Balance Sheet | ||||||
| Total Assets | 1.93B | 2.00B | 1.86B | 1.79B | 1.73B | 1.53B |
| Cash, Cash Equivalents and Short-Term Investments | 23.52M | 36.92M | 80.71M | 75.43M | 63.42M | 65.56M |
| Total Debt | 194.29M | 1.07B | 1.00B | 970.03M | 841.27M | 841.74M |
| Total Liabilities | 1.34B | 1.42B | 1.32B | 1.28B | 1.14B | 1.11B |
| Stockholders Equity | 537.27M | 530.85M | 491.89M | 469.34M | 485.92M | 361.23M |
Cash Flow | ||||||
| Free Cash Flow | 39.05M | -18.80M | -66.06M | 40.28M | -24.07M | -283.46M |
| Operating Cash Flow | 71.57M | 46.50M | 42.67M | 114.30M | 33.53M | 23.77M |
| Investing Cash Flow | 54.26M | -62.28M | 35.56M | -56.82M | 21.63M | -297.14M |
| Financing Cash Flow | -133.42M | -28.06M | -72.95M | -45.46M | -57.31M | 298.71M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | CHF3.80B | 13.95 | ― | 4.41% | -4.68% | -5.79% | |
70 Outperform | CHF3.71B | 18.99 | ― | 4.12% | 2.66% | 2.91% | |
66 Neutral | CHF1.55B | 39.86 | ― | 0.75% | 27.24% | 122.39% | |
57 Neutral | CHF1.19B | 73.80 | ― | 0.74% | -3.45% | -49.82% | |
55 Neutral | $13.29B | 17.42 | 10.03% | 0.93% | 7.13% | -12.93% | |
49 Neutral | CHF1.11B | 542.51 | ― | ― | 9.72% | ― |
AEVIS VICTORIA SA reported a significant increase in sales and free cash flow in the first half of 2025, allowing for substantial debt reduction. The company’s strategic initiatives, including the integration of Spital Zofingen and CentroMedico, have strengthened its market position, leading to sustainable growth across its healthcare and hospitality sectors. The company aims to resume its dividend policy in 2026, reflecting its improved financial health and market positioning.
The most recent analyst rating on (CH:AEVS) stock is a Hold with a CHF13.50 price target. To see the full list of analyst forecasts on AEVIS VICTORIA SA stock, see the CH:AEVS Stock Forecast page.
AEVIS VICTORIA SA reported strong financial performance in the first half of 2025, with a 17.7% increase in consolidated gross revenue and a 17.9% rise in net revenue compared to the previous year. The company achieved significant free cash flow and reduced debt through asset sales, and anticipates positive net results, with EBITDAR and EBITDA projections indicating continued growth.
The most recent analyst rating on (CH:AEVS) stock is a Hold with a CHF13.50 price target. To see the full list of analyst forecasts on AEVIS VICTORIA SA stock, see the CH:AEVS Stock Forecast page.
AEVIS VICTORIA SA’s Swiss Medical Network reported a significant revenue growth of over 20% in the first half of 2025, reaching CHF 501.4 million. This growth is attributed to both organic expansion and the successful integration of Spital Zofingen and CentroMedico, highlighting the effectiveness of its expansion strategy. The company continues to develop its integrated care model with the announcement of the Aare-Netz in Aargau, reinforcing its regional growth strategy.
The most recent analyst rating on (CH:AEVS) stock is a Hold with a CHF13.50 price target. To see the full list of analyst forecasts on AEVIS VICTORIA SA stock, see the CH:AEVS Stock Forecast page.
MRH Switzerland AG, a subsidiary of AEVIS VICTORIA SA, reported a 3.7% increase in turnover to CHF 103.9 million in the first half of 2025, driven by organic growth. The company’s EBITDAR improved, reflecting strong demand in the premium segment and effective cost management. Key hotels exceeded expectations, highlighting the success of its flagship strategy. The company plans to continue investing in operational excellence to sustain value creation.
The most recent analyst rating on (CH:AEVS) stock is a Hold with a CHF15.00 price target. To see the full list of analyst forecasts on AEVIS VICTORIA SA stock, see the CH:AEVS Stock Forecast page.